In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Norsk Hydro AS

Latest From Norsk Hydro AS

Clavis Pharma AS

Norwegian biotechnology company Clavis Pharma was spun out of Norsk Hydro in August 2001 to commercialize Lipid Vector Technology (LVT). LVT conjugates fatty acids to existing therapeutics to improve their ability to enter target cells. Clavis' first product is an LVT derivative of Ara-C, a common chemotherapy for blood cancers, which the firm is testing in solid tumor indications.
BioPharmaceutical Europe

Selected Start-Ups (7/02)

In Vivo briefly summarizes the technologies of these recently founded companies: AgaMatrix Inc., BioMark Diagnostics Inc., CareX SA, ConPharma AS, GenPath and Nanoplex Technologies Inc.
See All

Company Information

  • Industry
  • Diversified
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Norway
  • Parent & Subsidiaries
  • Norsk Hydro AS
  • Senior Management
  • George Sturmer, CFO
    Torvild Aakvaag, Pres.
    Sven Arild Andersen, Head, Biomedical Div.
    Ole Julian Eilersten, VP, Mktg.
  • Contact Info
  • Norsk Hydro AS
    Phone: (47) 22 53 81 00
    Bygdøy alle 2
    , N-0240